Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2021 1
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Wierzbicki K, et al. Among authors: cantor e. Curr Oncol Rep. 2020 Feb 6;22(2):19. doi: 10.1007/s11912-020-0877-0. Curr Oncol Rep. 2020. PMID: 32030483 Free PMC article. Review.
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Nand Yadav V, Ravindran R, Bruzek AK, Wadden J, John V, May Babila C, Cummings JR, Rahman Kawakibi A, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venneti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner SL, Koschmann C. Cantor E, et al. Neuro Oncol. 2022 Aug 1;24(8):1366-1374. doi: 10.1093/neuonc/noac030. Neuro Oncol. 2022. PMID: 35137228 Free PMC article. Clinical Trial.
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Gardner SL, Tarapore RS, Allen J, McGovern SL, Zaky W, Odia Y, Daghistani D, Diaz Z, Hall MD, Khatib Z, Koschmann C, Cantor E, Kurokawa R, MacDonald TJ, Aguilera D, Vitanza NA, Mueller S, Kline C, Lu G, Allen JE, Khatua S. Gardner SL, et al. Among authors: cantor e. Neurooncol Adv. 2022 Sep 13;4(1):vdac143. doi: 10.1093/noajnl/vdac143. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36382108 Free PMC article.
Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.
Schwark K, Messinger D, Cummings JR, Bradin J, Kawakibi A, Babila CM, Lyons S, Ji S, Cartaxo RT, Kong S, Cantor E, Koschmann C, Yadav VN. Schwark K, et al. Among authors: cantor e. Front Oncol. 2022 Aug 1;12:922928. doi: 10.3389/fonc.2022.922928. eCollection 2022. Front Oncol. 2022. PMID: 35978801 Free PMC article. Review.
Correction to: Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Wierzbicki K, et al. Among authors: cantor e. Curr Oncol Rep. 2020 Apr 16;22(5):47. doi: 10.1007/s11912-020-00912-z. Curr Oncol Rep. 2020. PMID: 32297022
A novel ATXN1-DUX4 fusion expands the spectrum of 'CIC-rearranged sarcoma' of the CNS to include non-CIC alterations.
Pratt D, Kumar-Sinha C, Cieślik M, Mehra R, Xiao H, Shao L, Franson A, Cantor E, Chinnaiyan AM, Mody R, Abdullaev Z, Aldape K, Quezado M, Camelo-Piragua S. Pratt D, et al. Among authors: cantor e. Acta Neuropathol. 2021 Apr;141(4):619-622. doi: 10.1007/s00401-021-02278-3. Epub 2021 Feb 7. Acta Neuropathol. 2021. PMID: 33550509 No abstract available.
11 results